黑料网

Predictive Oncology (NASDAQ: POAI) announced progress in its strategic alternatives evaluation, initiated on November 13, 2024. The company is exploring options including potential sale, asset sales, mergers, licensing agreements, or strategic investments to maximize shareholder value. Multiple confidential discussions are ongoing with prospective partners, involving due diligence. The company's assets include a biobank of over 150,000 tumor samples, 200,000 pathology slides, and longitudinal drug response data, which management believes are undervalued at current market prices. While discussions are ongoing with multiple parties, there's no guarantee of any transaction or specific timing.

Predictive Oncology (POAI) reported Q3 2024 financial results with a loss from continuing operations of $2.3 million on revenue of $345,686, down from $676,626 in Q3 2023. The company ended Q3 with $3.1 million in cash and cash equivalents, compared to $8.7 million at end-2023. Key developments include initiating a strategic alternatives review process to maximize shareholder value, implementing a 20% cost reduction initiative, and raising $1.3 million through warrant exercises. The company validated its biobank's long-term sample viability and entered the $51.5 billion biomarker discovery market following successful studies.

Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is set to participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. The company will deliver a virtual presentation available on-demand starting September 9th at 7:00 am ET via the conference platform.

Additionally, the Predictive Oncology management team will be available for one-on-one meetings with investors during the conference. Interested investors are advised to contact their H.C. Wainwright representative to schedule a meeting. This event provides an opportunity for POAI to showcase its innovations in AI-driven drug discovery and connect with potential investors.

Predictive Oncology Inc. (NASDAQ: POAI) has announced successful study results demonstrating the long-term stability and viability of over 150,000 cryopreserved patient tumor samples in its proprietary biobank. The study showed 100% concordance in drug response results between original fresh patient sample testing and long-term cryogenically stored tumor material, some preserved for up to 16 years.

This validation is important for predicting patient outcomes, guiding personalized therapies, target validation, and in silico modeling of drug-tumor responses. The company's biobank, containing 150,000+ tumor specimens, 200,000+ pathology slides, and 20 years of actionable data, positions Predictive Oncology as a key player in AI-driven drug discovery. The global biospecimen market, valued at $4.4 billion in 2023, is expected to reach $11.7 billion by 2031, growing at a CAGR of over 13%.

Predictive Oncology (Nasdaq: POAI) reported Q2 2024 financial results, with a net loss of $3.2 million on total revenue of $0.3 million. Key highlights include:

1. Entry into the biomarker discovery market, estimated at $51.5 billion in 2024, following successful development of multi-omic machine learning models for ovarian cancer.

2. Implementation of a cost savings initiative expected to reduce cash used in operating activities by 20% annually.

3. Cash and cash equivalents of $5.3 million as of June 30, 2024.

4. Revenue decrease to $278,722 in Q2 2024 from $490,110 in Q2 2023.

5. Gross profit margin declined to 45% from 67% year-over-year.

6. Reduced expenses across general and administrative, operations, and sales and marketing categories.

Predictive Oncology Inc. (NASDAQ: POAI) has expanded applications for its AI-driven drug discovery platform to address patient heterogeneity and improve drug development success rates. The company's approach integrates artificial intelligence, machine learning, and a biobank of cryopreserved patient-derived tumor samples to introduce patient heterogeneity earlier in the drug discovery process. This strategy aims to increase the Probability of Technical Success (PTS) for drug candidates, potentially reducing failures in late-stage clinical trials.

The platform's capabilities include comprehensive patient sample response analysis, biomarker discovery, clinical trial optimization, and target validation. By leveraging these tools, Predictive Oncology seeks to help pharmaceutical companies make more informed decisions about drug development, potentially accelerating timelines and improving resource allocation in oncology R&D.

Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging AI and machine learning for oncology drug discovery, has announced it will report its Q2 2024 financial results on Wednesday, August 14, 2024, before market open. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET on the same day.

Investors can access the call via toll-free (877-407-3982) or international (201-493-6780) numbers, using Conference ID 13748154. A live webcast will also be available on the company's investor relations website.

Predictive Oncology Inc. (NASDAQ: POAI) has announced a definitive agreement for the exercise of existing warrants to purchase 958,117 shares of common stock at a reduced price of $1.32 per share, down from the original $14.00. This exercise is expected to generate gross proceeds of approximately $1.26 million for the company. In return, Predictive Oncology will issue new unregistered Series A and B warrants, each for up to 958,117 shares, with an exercise price of $1.07 per share.

The transaction, set to close around July 26, 2024, will provide working capital for the company. This funding, combined with $3.58 million raised in May 2024 through an at-the-market facility, will be used for general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for this transaction.

Predictive Oncology Inc. (NASDAQ: POAI) has announced its expansion into the biomarker discovery market, leveraging its AI/ML-driven drug discovery platform. This move follows successful results from a retrospective ovarian cancer study with UPMC Magee-Womens Hospital, presented at the 2024 ASCO Annual Meeting. The study demonstrated the company's ability to develop multi-omic machine learning models that more accurately predict patient survival outcomes compared to clinical data alone.

The company aims to discover novel biomarkers for predicting patient outcomes and drug responses in oncology, with potential applications beyond ovarian cancer. This initiative is expected to create additional revenue streams and enhance the value of Predictive Oncology's diverse patient samples and data. The total biomarker discovery market is estimated to be $51.5 billion in 2024.